Expertise in
18
conditions

Dr. Brent M. Boyce

Brent M Boyce MD PC
Sebewaing, MI
Expertise in
18
conditions
Specialties:Dermatology
Accepting New Patients
Expertise in
18
conditions
OverviewInsuranceLocationsClinical Research

Overview

Brent Boyce is a Dermatologist in Sebewaing, Michigan. Mr. Boyce is highly rated in 18 conditions, according to our data. His top areas of expertise are Plaque Psoriasis, Psoriasis, Guttate Psoriasis, and Seborrheic Keratosis. Mr. Boyce is currently accepting new patients.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Dermatology
Licenses
Dermatology in MI
Hospital Affiliations
Scheurer Hospital
Mclaren Thumb Region
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Priority Health
  •  Blue Cross Blue Shield
  •  McLaren Health
  •  Humana

Locations

BRENT M BOYCE MD PC
106 E Main St, Sebewaing, MI 48759
989-883-3800

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Severe or Very Severe Alopecia Areata
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Active_not_recruiting
Publish Date: January 23, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Biological, Other
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
Enrollment Status: Completed
Publish Date: February 15, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 8 Less Clinical Trials

2 Total Publications

Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis.
Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis.
Journal: Acta dermato-venereologica
Published: January 17, 2015
Similar Doctors
Expertise in
50
conditions
Dr. David B. O'donnell
Dermatology
Expertise in
50
conditions
Dr. David B. O'donnell
Dermatology
4705 Towne Centre Rd, Suite 301, 
Saginaw, MI 
 (31.2 mi)
989-793-6505
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David O'donnell is a Dermatologist in Saginaw, Michigan. Dr. O'donnell is highly rated in 50 conditions, according to our data. His top areas of expertise are Basal Cell Skin Cancer, Squamous Cell Skin Carcinoma, Sebaceous Adenoma, and Extramammary Paget Disease. Dr. O'donnell is currently accepting new patients.

Expertise in
41
conditions
Dr. Kevin J. Gaffney
Dermatology
Expertise in
41
conditions
Dr. Kevin J. Gaffney
Dermatology
1352 S Linden Rd, 
Flint, MI 
 (52.7 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kevin Gaffney is a Dermatologist in Flint, Michigan. Dr. Gaffney is highly rated in 41 conditions, according to our data. His top areas of expertise are Sebaceous Adenoma, Syringoma, Syringocystadenoma Papilliferum, and Papular Urticaria. Dr. Gaffney is currently accepting new patients.

Expertise in
27
conditions
Dr. Jennifer R. Nash
Dermatology
Expertise in
27
conditions
Dr. Jennifer R. Nash
Dermatology

Jennifer Nash MD Dermatology Associates Of Midland, Plc

2711 W Wackerly St, 
Midland, MI 
 (40.8 mi)
989-837-6868
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jennifer Nash is a Dermatologist in Midland, Michigan. Dr. Nash is highly rated in 27 conditions, according to our data. Her top areas of expertise are Actinic Keratosis, Sunburn, Hidradenitis Suppurativa, and Psoriasis. Dr. Nash is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile